The FDA-mandated trial provides reassurance about risk of cardiovascular events, but only for middle-aged or older men with confirmed hypogonadism.
A new series of studies provides the strongest evidence to date of cardiovascular risk associated with an artificial sweetener. The researchers call for revisiting food labeling requirements and more safety studies of sugar substitutes.
A new review by an American College of Cardiology working group urges a nuanced approach in counseling women about the benefits and risks of hormone therapy from a cardiology perspective.
Randomized trial evidence that weight loss can yield cardiovascular benefits independent of antidiabetic effects has been elusive. Two major ongoing trials are likely to change that, with potentially big implications for clinical practice.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A new study suggests that plasma levels of this gut microbial metabolite might help further stratify cardiovascular risk when characterizing patients’ response to statin therapy.
A metabolite of the essential amino acid phenylalanine has been shown to play an important role in driving cardiovascular disease by enhancing platelet reactivity and acting upon platelet adrenergic receptors.
This automimmune condition isn’t traditionally associated with cardiac disease, but overt cardiac involvement confers a five-year mortality risk of up to 70%. Experts share screening and treatment guidance.
Patients live with the disease for decades and need increasingly complicated treatment regimens to attain glycemic goals. But other goals such as cardiovascular risk reduction, weight control, and avoidance of hypoglycemia also need consideration.
A large matched-cohort study in patients with type 2 diabetes and obesity finds that metabolic surgery confers significant improvements in all prespecified events plus marked reductions in weight, HbA1c, and use of diabetes and cardiovascular medications.
Two new studies take significant steps toward interventions to reduce cardiac risk in humans by reducing levels of the metabolite TMAO through diet manipulation or targeted therapies.